Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: A cross-sectional study

被引：2

作者：

Hasnain M.G. ^{[1
,2
]}

Nath P. ^{[3
]}

Maruf S. ^{[1
]}

Nabi S.G. ^{[4
]}

Hossain A.F.M.A. ^{[5
]}

Ahmed B.-N. ^{[6
]}

Mondal D. ^{[1
]}

Basher A. ^{[7
]}

机构：

[1] Nutrition and Clinical Service Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (Icddr, B), Dhaka

[2] Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle (UoN), Callaghan, NSW

[3] Infection and Tropical Medicine, Mymensingh Medical College and Hospital (MMCH), Mymensingh

[4] Mugda Medical College and Hospital, Dhaka

[5] National Kala-azar Elimination Program (NKEP), Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka

[6] Co-ordination and Support Centre (CSC), Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB), Dhaka

[7] Critical Care Medicine (CCM), Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka

来源：

BMC Research Notes | / 11卷 / 1期

关键词：

Amphotericin B deoxycholate; Bangladesh; Treatment outcome; Visceral leishmaniasis;

D O I：

10.1186/s13104-018-4036-8

中图分类号：

学科分类号：

摘要：

Objective: Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result: Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh. © 2018 The Author(s).

引用

共 21 条

[1] Chowdhury R., Mondal D., Chowdhury V., Faria S., Alvar J., Nabi S.G., Boelaert M., Dash A.P., How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data, PLOS Negl Trop Dis, 8, 8, (2014)
[2] Health Ministers Commit to Eliminating Kala-azar [Media Advisory], (2014)
[3] Report of A WHO Consultation of Partners, (2015)
[4] Chowdhury M.A.J., Alam M.N., Hussain A., Rafiquddin A.K., Rahman K.M.A., A study on the treatment of Bangladeshi Kala-azar patients with different dosage regiments of sodium antimony gluconate, Bangl J Med, 4, 1, pp. 1-5, (1993)
[5] Vanlerberghe V., Diap G., Guerin P.J., Meheus F., Gerstl S., Van Der Stuyft P., Boelaert M., Drug policy for visceral leishmaniasis: A cost-effectiveness analysis, Trop Med Int Health., 12, 2, pp. 274-283, (2007)
[6] Sundar S., Chakravarty J., An update for pharmacotherapy on leishmaniasis, Exp Opin Pharmacother, 16, 2, pp. 237-252, (2015)
[7] Sundar S., Mehta H., Suresh A.V., Singh S.P., Madhukar R., Murray H.W., Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations, Clin Infect Dis, 38, 3, pp. 377-383, (2004)
[8] Gilead Sciences and World Health Organization Establish New 5-year Initiative to Prevent Deaths from Visceral Leishmaniasis (News Release), (2011)
[9] Cheeren M.M., Sundar S., Rijal S., Faiz A., Millet P., Oliaro P., A review of clinical trials of treatment for visceral leishmaniasis in the Indian sub-continent (Bangladesh, India and Nepal), Trop IKA Net., 1, 1, pp. 1-31, (2010)
[10] National Uideline for Kala-azar Case Management, (2015)

← 1 2 3 →